Inovio Pharmaceuticals closed at $1.62 on Nov 4, down 2.41%, 37.7% below its 52-week closing high. Volume of 21.4M shares was 1.00× its 20-day average (close to normal).
Split-adjusted performance: +43.4% over one month, +30.6% over six months, -35.2% over one year.
Short interest was 21.3M shares at the Oct 15 settlement, up 2.3% from the prior report (26.3% of float, 6.9 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| INOInovio Pharmaceuticals | $1.62 | −2.41% | +30.6% | — | — | — | $167.5M | |
| ZNTLZentalis Pharmaceuticals | $1.76 | −1.12% | −57.9% | — | — | — | $166.6M | Compare |
| SIONSionna Therapeutics | $3.73 | +2.19% | −91.4% | — | — | — | $168.6M | Compare |
| PEPGPepGen | $2.45 | −0.41% | +32.8% | — | — | — | $169.7M | Compare |
| ORMPOramed Pharmaceuticals | $4.13 | +3.25% | +5.4% | — | — | 1.0 | $171.8M | Compare |
| ANTXAN2 Therapeutics | $4.25 | +1.67% | −8.6% | — | — | — | $160.4M | Compare |
| WHWKWhitehawk Therapeutics | $3.17 | +2.26% | −23.6% | — | — | — | $180.7M | Compare |
| BBOTBridgeBio Oncology Therapeutics | $2.30 | −0.86% | −72.4% | — | — | — | $184.4M | Compare |
| ALXOALX Oncology Holdings | $1.36 | +5.43% | −34.9% | — | — | — | $188.1M | Compare |
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
